Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 1.53
HALO's Cash-to-Debt is ranked lower than
75% of the 1046 Companies
in the Global Biotechnology industry.

( Industry Median: 55.72 vs. HALO: 1.53 )
Ranked among companies with meaningful Cash-to-Debt only.
HALO' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.84  Med: No Debt Max: No Debt
Current: 1.53
0.84
No Debt
Equity-to-Asset 0.20
HALO's Equity-to-Asset is ranked lower than
88% of the 767 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. HALO: 0.20 )
Ranked among companies with meaningful Equity-to-Asset only.
HALO' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.65  Med: 0.27 Max: 0.97
Current: 0.2
-1.65
0.97
Debt-to-Equity 2.86
HALO's Debt-to-Equity is ranked lower than
96% of the 494 Companies
in the Global Biotechnology industry.

( Industry Median: 0.26 vs. HALO: 2.86 )
Ranked among companies with meaningful Debt-to-Equity only.
HALO' s Debt-to-Equity Range Over the Past 10 Years
Min: -17.7  Med: 1.08 Max: 20.98
Current: 2.86
-17.7
20.98
Debt-to-EBITDA -3.27
HALO's Debt-to-EBITDA is ranked lower than
99.99% of the 214 Companies
in the Global Biotechnology industry.

( Industry Median: 1.94 vs. HALO: -3.27 )
Ranked among companies with meaningful Debt-to-EBITDA only.
HALO' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -3.27  Med: -0.82 Max: -0.59
Current: -3.27
-3.27
-0.59
Piotroski F-Score: 4
Altman Z-Score: 3.73
Beneish M-Score: -3.71
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -40.65
HALO's Operating Margin % is ranked higher than
58% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -105.96 vs. HALO: -40.65 )
Ranked among companies with meaningful Operating Margin % only.
HALO' s Operating Margin % Range Over the Past 10 Years
Min: -740.79  Med: -136.74 Max: -20.33
Current: -40.65
-740.79
-20.33
Net Margin % -53.17
HALO's Net Margin % is ranked higher than
55% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -92.13 vs. HALO: -53.17 )
Ranked among companies with meaningful Net Margin % only.
HALO' s Net Margin % Range Over the Past 10 Years
Min: -628.84  Med: -139.44 Max: -23.86
Current: -53.17
-628.84
-23.86
ROE % -1600.63
HALO's ROE % is ranked lower than
99% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: -39.05 vs. HALO: -1600.63 )
Ranked among companies with meaningful ROE % only.
HALO' s ROE % Range Over the Past 10 Years
Min: -1958.98  Med: -284.98 Max: -59.11
Current: -1600.63
-1958.98
-59.11
ROA % -29.98
HALO's ROA % is ranked higher than
52% of the 1052 Companies
in the Global Biotechnology industry.

( Industry Median: -32.93 vs. HALO: -29.98 )
Ranked among companies with meaningful ROA % only.
HALO' s ROA % Range Over the Past 10 Years
Min: -75.94  Med: -52.25 Max: -18.54
Current: -29.98
-75.94
-18.54
ROC (Joel Greenblatt) % -528.52
HALO's ROC (Joel Greenblatt) % is ranked lower than
52% of the 1014 Companies
in the Global Biotechnology industry.

( Industry Median: -432.52 vs. HALO: -528.52 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
HALO' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2382.35  Med: -1357.73 Max: -173.83
Current: -528.52
-2382.35
-173.83
3-Year Revenue Growth Rate 33.10
HALO's 3-Year Revenue Growth Rate is ranked higher than
81% of the 592 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. HALO: 33.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
HALO' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 34.1 Max: 232.2
Current: 33.1
0
232.2
3-Year EBITDA Growth Rate -3.90
HALO's 3-Year EBITDA Growth Rate is ranked lower than
58% of the 701 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. HALO: -3.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
HALO' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 7.8 Max: 97.2
Current: -3.9
0
97.2
3-Year EPS without NRI Growth Rate 3.10
HALO's 3-Year EPS without NRI Growth Rate is ranked higher than
55% of the 683 Companies
in the Global Biotechnology industry.

( Industry Median: -1.10 vs. HALO: 3.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
HALO' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 3.1 Max: 43.4
Current: 3.1
0
43.4
» HALO's 30-Y Financials

Financials (Next Earnings Date: 2018-02-28)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2017

HALO Guru Trades in Q1 2017

Louis Moore Bacon 50,000 sh (+33.33%)
Jim Simons Sold Out
First Eagle Investment 7,394,315 sh (-3.81%)
Ken Fisher 616,511 sh (-6.99%)
Murray Stahl 30,628 sh (-25.60%)
» More
Q2 2017

HALO Guru Trades in Q2 2017

Paul Tudor Jones 46,103 sh (New)
John Paulson 111,100 sh (New)
Louis Moore Bacon 100,000 sh (+100.00%)
Murray Stahl 30,629 sh (unchged)
First Eagle Investment 7,394,315 sh (unchged)
Ken Fisher 614,021 sh (-0.40%)
» More
Q3 2017

HALO Guru Trades in Q3 2017

Louis Moore Bacon Sold Out
John Paulson Sold Out
Ken Fisher 583,221 sh (-5.02%)
First Eagle Investment 6,444,981 sh (-12.84%)
Murray Stahl 23,607 sh (-22.93%)
Paul Tudor Jones 18,765 sh (-59.30%)
» More
Q4 2017

HALO Guru Trades in Q4 2017

Jim Simons 736,600 sh (New)
Paul Tudor Jones 30,637 sh (+63.27%)
Ken Fisher 560,373 sh (-3.92%)
Murray Stahl 19,208 sh (-18.63%)
First Eagle Investment 4,531,081 sh (-29.70%)
» More
» Details

Insider Trades

Latest Guru Trades with HALO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
First Eagle Investment 2017-12-31 Reduce -29.70%0.07%$16.75 - $20.8 $ 18.541%4,531,081
Ken Fisher 2017-12-31 Reduce -3.92%$16.75 - $20.8 $ 18.541%560,373
First Eagle Investment 2017-09-30 Reduce -12.84%0.03%$11.76 - $17.4 $ 18.5438%6,444,981
Ken Fisher 2017-09-30 Reduce -5.02%$11.76 - $17.4 $ 18.5438%583,221
John Paulson 2017-09-30 Sold Out 0.02%$11.76 - $17.4 $ 18.5438%0
Ken Fisher 2017-06-30 Reduce -0.40%$11.8 - $14.89 $ 18.5439%614,021
John Paulson 2017-06-30 New Buy0.02%$11.8 - $14.89 $ 18.5439%111,100
First Eagle Investment 2017-03-31 Reduce -3.81%0.01%$9.99 - $14.68 $ 18.5447%7,394,315
Ken Fisher 2017-03-31 Reduce -6.99%$9.99 - $14.68 $ 18.5447%616,511
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Halozyme Therapeutics Inc does not have enough historical financial data to display Peter Lynch Chart.

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:NAS:FOLD, SZSE:300347, NAS:GBT, SZSE:300009, XTER:MOR, SHSE:603233, NAS:PBYI, NAS:ARRY, XKRX:086900, NAS:CORT, NAS:ANAB, NYSE:EBS, SZSE:002603, NAS:IMMU, HKSE:00570, XSWX:GALE, SHSE:600161, NAS:RARE, XKRX:006280, NAS:SPPI » details
Traded in other countries:RV7.Germany,
Headquarter Location:USA
Halozyme Therapeutics Inc is a biotechnology company. It is engaged in research on human enzymes that alter the extracellular matrix and tumor environment.

Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Guru Investment Theses on Halozyme Therapeutics Inc

First Eagle Fund of America Comments on Halozyme Therapeutics - Oct 31, 2017

Halozyme Therapeutics (NASDAQ:HALO) announced new licensing agreements with Roche and with Bristol-Myers-Squibb for its ENHANZE drug-delivery technology. Following these agreements, which include upfront and milestone payments, as well as long-term royalty streams, Halozyme increased its cash-balance guidance for the year. Halozyme has two main parts to its business: a drug-delivery technology that has been profitable and growing, and a proprietary exploratory oncology pipeline.



From First Eagle Fund of America third quarter 2017 shareholder commentary.



Check out First Eagle Investment latest stock trades

Top Ranked Articles about Halozyme Therapeutics Inc

Halozyme To Host Fourth Quarter And Full-Year 2017 Financial Results Conference Call
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Halozyme Therapeutics, Inc. (HALO)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Halozyme Therapeutics, Inc. - HALO
Halozyme Projects 25 To 30 Percent ENHANZE Royalty Growth In 2018
Halozyme Therapeutics To Present At The 36th Annual J.P. Morgan Healthcare Conference
Report: Developing Opportunities within Aramark, J.M. Smucker, Halozyme Therapeutics, Trinseo S.A, Camden Property Trust, and Lions Gate Entertainment — Future Expectations, Projections Moving into 2018
CORRECTING and REPLACING – Recent Analysis Shows Pure Storage, Catalent, Boyd Gaming, Halozyme Therapeutics, Clovis Oncology, and General Cable Market Influences – Renewed Outlook, Key Drivers of Growth
Recent Analysis Shows Pure Storage, Catalent, Boyd Gaming, Halozyme Therapeutics, Clovis Oncology, and General Cable Market Influences – Renewed Outlook, Key Drivers of Growth
Halozyme To Present Nonclinical Data At SITC 2017 Supporting Combination Of PEGPH20 With Checkpoint Inhibitors
Halozyme Reports Third Quarter 2017 Results

Ratios

vs
industry
vs
history
PB Ratio 36.42
HALO's PB Ratio is ranked lower than
94% of the 944 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. HALO: 36.42 )
Ranked among companies with meaningful PB Ratio only.
HALO' s PB Ratio Range Over the Past 10 Years
Min: 7.06  Med: 28.96 Max: 148.72
Current: 36.42
7.06
148.72
PS Ratio 15.06
HALO's PS Ratio is ranked lower than
55% of the 731 Companies
in the Global Biotechnology industry.

( Industry Median: 11.11 vs. HALO: 15.06 )
Ranked among companies with meaningful PS Ratio only.
HALO' s PS Ratio Range Over the Past 10 Years
Min: 6.77  Med: 23.17 Max: 406.15
Current: 15.06
6.77
406.15
EV-to-EBIT -38.54
HALO's EV-to-EBIT is ranked lower than
99.99% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.83 vs. HALO: -38.54 )
Ranked among companies with meaningful EV-to-EBIT only.
HALO' s EV-to-EBIT Range Over the Past 10 Years
Min: -99.9  Med: -16.2 Max: -3.6
Current: -38.54
-99.9
-3.6
EV-to-EBITDA -39.95
HALO's EV-to-EBITDA is ranked lower than
99.99% of the 285 Companies
in the Global Biotechnology industry.

( Industry Median: 20.69 vs. HALO: -39.95 )
Ranked among companies with meaningful EV-to-EBITDA only.
HALO' s EV-to-EBITDA Range Over the Past 10 Years
Min: -105.6  Med: -16.6 Max: -3.6
Current: -39.95
-105.6
-3.6
EV-to-Revenue 15.23
HALO's EV-to-Revenue is ranked lower than
53% of the 776 Companies
in the Global Biotechnology industry.

( Industry Median: 12.21 vs. HALO: 15.23 )
Ranked among companies with meaningful EV-to-Revenue only.
HALO' s EV-to-Revenue Range Over the Past 10 Years
Min: 6.5  Med: 22 Max: 388.9
Current: 15.23
6.5
388.9
Current Ratio 3.46
HALO's Current Ratio is ranked lower than
56% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. HALO: 3.46 )
Ranked among companies with meaningful Current Ratio only.
HALO' s Current Ratio Range Over the Past 10 Years
Min: 1.81  Med: 6 Max: 41
Current: 3.46
1.81
41
Quick Ratio 3.37
HALO's Quick Ratio is ranked lower than
54% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 3.86 vs. HALO: 3.37 )
Ranked among companies with meaningful Quick Ratio only.
HALO' s Quick Ratio Range Over the Past 10 Years
Min: 1.81  Med: 5.97 Max: 41
Current: 3.37
1.81
41
Days Inventory 152.77
HALO's Days Inventory is ranked lower than
59% of the 494 Companies
in the Global Biotechnology industry.

( Industry Median: 126.17 vs. HALO: 152.77 )
Ranked among companies with meaningful Days Inventory only.
HALO' s Days Inventory Range Over the Past 10 Years
Min: 99.19  Med: 397.96 Max: 936.48
Current: 152.77
99.19
936.48
Days Sales Outstanding 32.30
HALO's Days Sales Outstanding is ranked higher than
78% of the 650 Companies
in the Global Biotechnology industry.

( Industry Median: 65.03 vs. HALO: 32.30 )
Ranked among companies with meaningful Days Sales Outstanding only.
HALO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 14.72  Med: 68.65 Max: 302.53
Current: 32.3
14.72
302.53
Days Payable 47.86
HALO's Days Payable is ranked lower than
56% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 59.19 vs. HALO: 47.86 )
Ranked among companies with meaningful Days Payable only.
HALO' s Days Payable Range Over the Past 10 Years
Min: 39.33  Med: 1086.78 Max: 10691.1
Current: 47.86
39.33
10691.1

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -4.20
HALO's 3-Year Average Share Buyback Ratio is ranked higher than
78% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. HALO: -4.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
HALO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -244.9  Med: -8.9 Max: -4.2
Current: -4.2
-244.9
-4.2

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 80.61
HALO's Price-to-Net-Cash is ranked lower than
93% of the 566 Companies
in the Global Biotechnology industry.

( Industry Median: 7.67 vs. HALO: 80.61 )
Ranked among companies with meaningful Price-to-Net-Cash only.
HALO' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 6.5  Med: 27.3 Max: 288.5
Current: 80.61
6.5
288.5
Price-to-Net-Current-Asset-Value 38.63
HALO's Price-to-Net-Current-Asset-Value is ranked lower than
89% of the 694 Companies
in the Global Biotechnology industry.

( Industry Median: 7.04 vs. HALO: 38.63 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
HALO' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 6.07  Med: 25.33 Max: 546
Current: 38.63
6.07
546
Price-to-Tangible-Book 36.35
HALO's Price-to-Tangible-Book is ranked lower than
92% of the 864 Companies
in the Global Biotechnology industry.

( Industry Median: 5.30 vs. HALO: 36.35 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
HALO' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 6.03  Med: 23.69 Max: 116.17
Current: 36.35
6.03
116.17
Price-to-Median-PS-Value 0.65
HALO's Price-to-Median-PS-Value is ranked higher than
73% of the 629 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. HALO: 0.65 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
HALO' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.32  Med: 1.45 Max: 92
Current: 0.65
0.32
92
Earnings Yield (Greenblatt) % -2.59
HALO's Earnings Yield (Greenblatt) % is ranked higher than
64% of the 1050 Companies
in the Global Biotechnology industry.

( Industry Median: -7.37 vs. HALO: -2.59 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
HALO' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -28  Med: -6.2 Max: -1
Current: -2.59
-28
-1

More Statistics

Revenue (TTM) (Mil) $166.05
EPS (TTM) $ -0.69
Beta3.15
Short Percentage of Float11.24%
52-Week Range $11.41 - 21.13
Shares Outstanding (Mil)142.36

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 301 182 216
EBIT (Mil $)
EBITDA (Mil $)
EPS ($) 0.27 -0.49 0.01 0.14
EPS without NRI ($) 0.27 -0.49 0.01 0.14
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAN
Positive CFROAN
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}